Abstract
Adoptive immunotherapy is considered a promising strategy for the treatment of metastatic tumors and current research efforts are directed to define the optimal approach and facilitate the transferability from preclinical to clinical settings. Among several approaches it is possible to schematically distinguish strategies based on either MHC-restricted or MHC-unrestricted immune effectors. The first are mainly based on the infusion of tumor-specific T lymphocytes capable of recognizing determined MHC-restricted tumor associated antigens (TAA) through their T cell receptor. MHC-unrestricted approaches do not target specific tumor associated antigens and are mainly mediated by effectors of the innate immune system, like natural killer (NK) cells or NKT cells, first barrier against pathogens and tumorigenesis processes, or by ex vivo activated lymphocytes like cytokine-induced killer (CIK) cells. MHC-unrestricted effectors are usually more abundant than TAA-specific precursors and easier to expand. Furthermore their activity is not restricted to precise HLAhaplotypes, not limited to a single tumor histotype and could overcome downregulation of MHC molecules operated by tumor cells as immune escape mechanism.
In this review we will discuss the main cancer immunotherapy strategies based on MHC-unrestricted immune effectors. The topic will be approached from the angle of ex vivo expansion protocols in clinical prospective, as well as potential approaches to favorably modulate their functions.
Keywords: Adoptive immunotherapy, MHC-unrestricted activity, NK, CIK, NKT.
Anti-Cancer Agents in Medicinal Chemistry
Title:Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy
Volume: 14 Issue: 2
Author(s): Valeria Leuci, Giulia Mesiano, Loretta Gammaitoni, Maja Todorovic, Lidia Giraudo, Fabrizio Carnevale-Schianca, Massimo Aglietta and Dario Sangiolo
Affiliation:
Keywords: Adoptive immunotherapy, MHC-unrestricted activity, NK, CIK, NKT.
Abstract: Adoptive immunotherapy is considered a promising strategy for the treatment of metastatic tumors and current research efforts are directed to define the optimal approach and facilitate the transferability from preclinical to clinical settings. Among several approaches it is possible to schematically distinguish strategies based on either MHC-restricted or MHC-unrestricted immune effectors. The first are mainly based on the infusion of tumor-specific T lymphocytes capable of recognizing determined MHC-restricted tumor associated antigens (TAA) through their T cell receptor. MHC-unrestricted approaches do not target specific tumor associated antigens and are mainly mediated by effectors of the innate immune system, like natural killer (NK) cells or NKT cells, first barrier against pathogens and tumorigenesis processes, or by ex vivo activated lymphocytes like cytokine-induced killer (CIK) cells. MHC-unrestricted effectors are usually more abundant than TAA-specific precursors and easier to expand. Furthermore their activity is not restricted to precise HLAhaplotypes, not limited to a single tumor histotype and could overcome downregulation of MHC molecules operated by tumor cells as immune escape mechanism.
In this review we will discuss the main cancer immunotherapy strategies based on MHC-unrestricted immune effectors. The topic will be approached from the angle of ex vivo expansion protocols in clinical prospective, as well as potential approaches to favorably modulate their functions.
Export Options
About this article
Cite this article as:
Leuci Valeria, Mesiano Giulia, Gammaitoni Loretta, Todorovic Maja, Giraudo Lidia, Carnevale-Schianca Fabrizio, Aglietta Massimo and Sangiolo Dario, Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (2) . https://dx.doi.org/10.2174/18715206113136660371
DOI https://dx.doi.org/10.2174/18715206113136660371 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transgenic Mouse Models of Parkinsons Disease and Huntingtons Disease
CNS & Neurological Disorders - Drug Targets Release of a Poorly Soluble Drug from Cross-Linked β-Cyclodextrin-Based Polymer Pellets Prepared via Extrusion/Spheronisation
Letters in Drug Design & Discovery Oxidative Brain Damage by Peroxynitrite in Bacterial Meningitis: A Target for Adjunctive Therapy?
Current Medicinal Chemistry - Central Nervous System Agents Changes of Drug Metabolizing Enzymes in the Liver of Male Sheep Exposed to either Cypermethrin or Dimethoate
Drug Metabolism Letters Molecular Interaction Study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 Kinase and JNK Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Current Molecular Pharmacology The Many Antithrombotic Actions of Nitric Oxide
Current Drug Targets Adaptors in Toll-Like Receptor Signaling and their Potential as Therapeutic Targets
Current Drug Targets Genomic and Genetic Approaches for the Identification of Antifungal Drug Targets
Infectious Disorders - Drug Targets Drug Binding Domains of MRP1 (ABCC1) as Revealed by Photoaffinity Labeling
Current Medicinal Chemistry - Anti-Cancer Agents Role of the Peroxynitrite - Poly (ADP-Ribose) Polymerase Pathway in the Pathogenesis of Liver Injury
Current Pharmaceutical Design Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Apoptosis: Potential Therapeutic Targets for New Drug Discovery
Current Medicinal Chemistry Influence of Vanin-1 and Catalytic Products in Liver During Normal and Oxidative Stress Conditions
Current Medicinal Chemistry Characterization of the Prostaglandin E2 Pathway in a Rat Model of Esophageal Adenocarcinoma
Current Cancer Drug Targets Pro- and Anti-Arrhythmic Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Heart in Sepsis: From Basic Mechanisms to Clinical Management
Current Vascular Pharmacology Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers
Current Pharmaceutical Design Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Adrenergic Modulation of Dendritic Cells Function: Relevance for the Immune Homeostasis
Current Neurovascular Research